Literature DB >> 22387306

Prophylactic pacemaker implantation in familial amyloid polyneuropathy.

Vincent Algalarrondo1, Sylvie Dinanian, Christophe Juin, Denis Chemla, Soumiya L Bennani, Claude Sebag, Violaine Planté, Dominique Le Guludec, Didier Samuel, David Adams, Michel S Slama.   

Abstract

BACKGROUND: Familial amyloid polyneuropathy (FAP) is an autosomic dominant disease with a high rate of conduction disorders and increased risk of sudden death. Prophylactic cardiac pacing may be considered in asymptomatic patients with FAP. However, the potential benefits are unknown.
OBJECTIVE: To document conduction disorders in a large series of FAP and the incidence of high-degree atrioventricular (AV) block in patients with prophylactic pacemaker (PM).
METHODS: From January 1999 to January 2010, 262 patients with FAP were retrospectively evaluated. Prophylactic PM was implanted in patients with His-ventricular interval ≥ 70 ms, His-ventricular interval >55 ms associated with a fascicular block, a first-degree AV block, or a Wenckebach anterograde point ≤ 100 beats/min. The spontaneous AV conduction was then analyzed by temporarily inhibiting the PM.
RESULTS: As compared with patients with prophylactic PM (n = 100) and patients implanted given a class I/IIa indication (n = 18), the patients who did not require PM (n = 144) were younger and displayed less severe cardiac involvement. Follow-up after prophylactic PM implantation was analyzed in 95 of the 100 patients over 45 ± 35 months, and a high-degree AV block was documented in 24 of the 95 patients (25%). The risk of high-degree AV block was higher in patients with first-degree AV block or Wenckebach anterograde point ≤ 100 beats/min (hazard ratio 3.5; 95% confidence interval 1.2-10) while microvoltage on surface electrocardiogram reduced the risk (hazard ratio 0.2; 95% confidence interval 0.1-0.7).
CONCLUSION: In FAP with conduction disorders, prophylactic PM implantation prevented major cardiac events in 25% of the patients over a 45-month mean follow-up. It is suggested that prophylactic PM implantation prevented symptomatic bradycardia in these patients.
Copyright © 2012 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22387306     DOI: 10.1016/j.hrthm.2012.02.033

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  16 in total

Review 1.  [Hereditary transthyretin amyloidosis].

Authors:  E Hund
Journal:  Nervenarzt       Date:  2014-10       Impact factor: 1.214

Review 2.  Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs.

Authors:  Adam Castaño; Brian M Drachman; Daniel Judge; Mathew S Maurer
Journal:  Heart Fail Rev       Date:  2015-03       Impact factor: 4.214

3.  Pacemaker implantation in familial amyloid polyneuropathy: when and for whom?

Authors:  James Milner; Rafaela Nicolau Teixeira; Ana Vera Marinho; Nuno Silva; Suzana Calretas; José Ferrão; Emanuel Furtado; Maria João Telo; Miguel Ventura; João Cristóvão; Luís Elvas; Guilherme Mariano Pêgo; Natália António
Journal:  J Interv Card Electrophysiol       Date:  2019-03-09       Impact factor: 1.900

Review 4.  Can Nuclear Imaging Techniques Predict Patient Outcome and Guide Medical Management in Hereditary Transthyretin Cardiac Amyloidosis?

Authors:  Vincent Algalarrondo; Eve Piekarski; Ludivine Eliahou; Dominique Le Guludec; Michel S Slama; François Rouzet
Journal:  Curr Cardiol Rep       Date:  2018-03-24       Impact factor: 2.931

Review 5.  FAP neuropathy and emerging treatments.

Authors:  David Adams; Marie Théaudin; Cecile Cauquil; Vincent Algalarrondo; Michel Slama
Journal:  Curr Neurol Neurosci Rep       Date:  2014-03       Impact factor: 5.081

Review 6.  Amyloid and the Heart.

Authors:  Aaron M Wolfson; Kevin S Shah; Jignesh K Patel
Journal:  Curr Cardiol Rep       Date:  2019-12-03       Impact factor: 2.931

7.  Senile systemic amyloidosis: clinical features at presentation and outcome.

Authors:  Jennifer H Pinney; Carol J Whelan; Aviva Petrie; Jason Dungu; Sanjay M Banypersad; Prayman Sattianayagam; Ashutosh Wechalekar; Simon D J Gibbs; Christopher P Venner; Nancy Wassef; Carolyn A McCarthy; Janet A Gilbertson; Dorota Rowczenio; Philip N Hawkins; Julian D Gillmore; Helen J Lachmann
Journal:  J Am Heart Assoc       Date:  2013-04-22       Impact factor: 5.501

Review 8.  Evolving landscape in the management of transthyretin amyloidosis.

Authors:  Philip N Hawkins; Yukio Ando; Angela Dispenzeri; Alejandra Gonzalez-Duarte; David Adams; Ole B Suhr
Journal:  Ann Med       Date:  2015-11-27       Impact factor: 4.709

Review 9.  First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy.

Authors:  David Adams; Ole B Suhr; Ernst Hund; Laura Obici; Ivailo Tournev; Josep M Campistol; Michel S Slama; Bouke P Hazenberg; Teresa Coelho
Journal:  Curr Opin Neurol       Date:  2016-02       Impact factor: 5.710

10.  Genotype-phenotype correlation and course of transthyretin familial amyloid polyneuropathies in France.

Authors:  Louise-Laure Mariani; Pierre Lozeron; Marie Théaudin; Zoia Mincheva; Aissatou Signate; Beatrice Ducot; Vincent Algalarrondo; Christian Denier; Clovis Adam; Guillaume Nicolas; Didier Samuel; Michel S Slama; Catherine Lacroix; Micheline Misrahi; David Adams
Journal:  Ann Neurol       Date:  2015-10-07       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.